BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Also Read: BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential BioNTech will pay Biotheus an upfront consideration of $800 million, predominantly in cash, with a small portion in American depositary shares, plus additional performance-based contingent payments of up to $150 million if certain milestones are met. The transaction is expected to close in the first quarter of 2025. The acquisition follows an initial exclusive global license and collaboration agreement between BioNTech and Biotheus, which closed in November 2023. The agreement granted BioNTech the rights to develop, manufacture, and commercialize BNT327/PM8002 globally ex-Greater China. The transaction is part of BioNTech's oncology strategy, which aims to enhance the company's capabilities to r
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi plans to change hospital drug-discount program, WSJ reports [Yahoo! Finance]Yahoo! Finance
- Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Citi, Santander Prep Up to €4 Billion Debt for Urbaser Buyout [Yahoo! Finance]Yahoo! Finance
- Male Infertility Business Research Report 2024: Global Market to Reach $6.5 Billion by 2030 - Focus on Reducing Stigma and Increasing Access Strengthens Growth Prospects [Yahoo! Finance]Yahoo! Finance
- Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients [Yahoo! Finance]Yahoo! Finance
SNY
Analyst Actions
- 9/19/24 - Citigroup Inc.
SNY
Sec Filings
- 11/18/24 - Form 6-K
- 11/7/24 - Form SC
- 11/7/24 - Form 6-K
- SNY's page on the SEC website